These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20569190)

  • 1. Henry S. Kaplan Distinguished Scientist Award Lecture 2007. The remarkable yin and yang of tumour hypoxia.
    Brown M
    Int J Radiat Biol; 2010 Nov; 86(11):907-17. PubMed ID: 20569190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy.
    Brown JM
    Br J Radiol; 2014 Mar; 87(1035):20130686. PubMed ID: 24338942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How can we overcome tumor hypoxia in radiation therapy?
    Harada H
    J Radiat Res; 2011; 52(5):545-56. PubMed ID: 21952313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia and cancer.
    Brahimi-Horn MC; Chiche J; Pouysségur J
    J Mol Med (Berl); 2007 Dec; 85(12):1301-7. PubMed ID: 18026916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypoxia and angiogenesis].
    Simon JM
    Bull Cancer; 2007 Jul; 94 Spec No():S160-5. PubMed ID: 17846000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting vasculogenesis after radiation: a new paradigm to improve local control by radiotherapy.
    Martin BJ
    Semin Radiat Oncol; 2013 Oct; 23(4):281-7. PubMed ID: 24012342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.
    Shi M; Guo XT; Shu MG; Chen FL; Li LW
    Med Hypotheses; 2007; 69(1):33-5. PubMed ID: 17280792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the molecular basis for tumour hypoxia.
    Carroll VA; Ashcroft M
    Expert Rev Mol Med; 2005 Apr; 7(6):1-16. PubMed ID: 15831177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas.
    Zips D; Le K; Yaromina A; Dörfler A; Eicheler W; Zhou X; Geyer P; Hilberg F; Baumann M
    Radiother Oncol; 2009 Sep; 92(3):405-10. PubMed ID: 19409639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical radiosensitizers for use in radiotherapy.
    Wardman P
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels.
    Harada H; Inoue M; Itasaka S; Hirota K; Morinibu A; Shinomiya K; Zeng L; Ou G; Zhu Y; Yoshimura M; McKenna WG; Muschel RJ; Hiraoka M
    Nat Commun; 2012 Apr; 3():783. PubMed ID: 22510688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology.
    Weinmann M; Welz S; Bamberg M
    Curr Med Chem Anticancer Agents; 2003 Sep; 3(5):364-74. PubMed ID: 12871083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion.
    Brahimi-Horn C; Pouysségur J
    Bull Cancer; 2006 Aug; 93(8):E73-80. PubMed ID: 16935775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour hypoxia: the picture has changed in the 1990s.
    Brown JM; Giaccia AJ
    Int J Radiat Biol; 1994 Jan; 65(1):95-102. PubMed ID: 7905916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia: targeting the tumour.
    Boyle RG; Travers S
    Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.
    Brown JM
    Cancer Res; 1999 Dec; 59(23):5863-70. PubMed ID: 10606224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor.
    Nordgren IK; Tavassoli A
    Chem Soc Rev; 2011 Aug; 40(8):4307-17. PubMed ID: 21483947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours.
    Weinmann M; Belka C; Plasswilm L
    Onkologie; 2004 Feb; 27(1):83-90. PubMed ID: 15007254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microenvironmental and cellular consequences of altered blood flow in tumours.
    Raghunand N; Gatenby RA; Gillies RJ
    Br J Radiol; 2003; 76 Spec No 1():S11-22. PubMed ID: 15456710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers.
    Bischoff P; Altmeyer A; Dumont F
    Expert Opin Ther Pat; 2009 May; 19(5):643-62. PubMed ID: 19441939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.